

# Cedrus' Head of Life Sciences Ms. Kimberly Nearing invited to speak at the BioCentury and Bayhelix's China Healthcare Summit 2018 in Shanghai

EN 繁 简

2018-12-05 09:00

HONG KONG, Dec. 5, 2018 /PRNewswire/ -- Ms. Kimberly Nearing, the **Managing Director - Life Sciences** at [Cedrus](#)



[Investments \("Cedrus"\)](#), was invited to speak on a panel at the 5<sup>th</sup> Annual **China Healthcare Summit in 2018 in Shanghai** hosted by **BioCentury Inc.** and **BayHelix**.

Five years ago, the first China Healthcare Summit asked how the nation would build the "**Bridge to Innovation**." In 2018, the focus of the summit was on how China is actually building the "bridge" to global healthcare. The full two-day program on 13<sup>th</sup> and 14<sup>th</sup> November highlighted by interchange among China-facing biotech innovators and their globally-facing Chinese counterparts, plus 35 roadshow presentations and 1-on-1 meetings. During the conference, **McKinsey & Co.** delivered the key findings from its **exclusive 5<sup>th</sup> China Healthcare Summit** report to conference delegates.

The China Healthcare Summit 2018 is among the most important healthcare conferences of the year and drew over 550 participants. Conference speakers and participants represented many leading investors and corporate executives in the region and overseas. They included Nisa Leung, Managing Partner, **Qiming Partners**; Bin Li, Ph.D., CEO, **Ally Bridge LB Healthcare Fund**; Lianshan Zhang, Ph.D., SVP and President, Global R&D, **Jiangsu Hengrui Medicine Co., Ltd.**; Ruilin Song, Executive President, **PhIRDA (China Pharmaceutical Innovation and Research Development Association)**; Hyunsang Muk, President & CEO, **Korea Drug Development Fund**; Jimmy Wei, Ph.D., Managing Partner in China, **Pivotal bioVenture Partners**; James Li, M.D., CEO, **JW Therapeutics Inc.**; Thomas Willemsen, Chairman, **GlaxoSmithKline (China) Investment Co. Ltd.**; and Antoine Papiernik, Managing Partner, **Sofinnova Partners**.

**Ms. Nearing participated in the summit's capstone rapporteur session**, where biotech leaders from the U.S., Europe, and Asia reflected on what they had learned about China's prospects for leadership at home and abroad in innovation and entrepreneurship.

## Featured Video

## Related Keywords:

[Biotechnology](#)[Health Care/Hospital](#)[Medical/Pharmaceuticals](#)

## Recent Releases

Cedrus' Head of Life Sciences Ms. Kimberly Nearing invited to speak at the BioCentury and Bayhelix's China Healthcare Summit 2018 in Shanghai  
2018-12-05

Cedrus Investments Signed Cooperation Agreement with Sinopharm Nutraceuticals Industrial (Shanghai) on 16th November 2018  
2018-11-21

Cedrus Investments Hosted Life Sciences Forum and Dinner  
2018-11-16

Cedrus Investments' Head of Life Sciences Ms. Kimberly Nearing invited to speak at LIFE SCIENCES SUMMIT IN NEW YORK CITY  
2018-11-05

Cedrus Investments' Head of Life Sciences Served as a Panelist and Judge at SAPA'S Pharma/biotech Investment Summit and Roadshow  
2018-06-26

Cedrus Investments' Chairman Mr. Rani Jarkas is Invited to Speak at the 121

Dr. C. Simone Fishburn, VP, Executive Editor at BioCentury Inc., said the capstone panel was "great [and she] got very enthusiastic feedback...and I think it was a perfect wrap to the conference."

#### About Cedrus Investments

[Cedrus Investments](#) is a global boutique investment firm headquartered in Hong Kong, specializing in [Asset Management](#) and [Financial Advisory Services](#). Cedrus has extensive experience and a global network in the life sciences industry together with cross-border transactions track record in geographies, including China, Australia, Asia, U.S., and Europe.

Media Enquiry:

Cedrus Investments Ltd.

Amy Sin

+852-3519-2828

[information@cedrusinvestments.com](mailto:information@cedrusinvestments.com)

Logo - <http://photos.prnasia.com/prnh/20150930/8521506461LOGO>

Source: Cedrus Investments

Tech Investment Conference in Hong Kong on Life Sciences

2018-05-15

[Go to MediaRoom](#)

#### Biotechnology Recent Releases

Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints

2018-12-13

WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity

2018-12-12

Tissue Genesis Introduces State-of-the-Art Icellator(R) X

2018-12-11

Cathay Industrial Biotech Invests an Additional USD 500 Million to Expand its Production Capacity for New Bio-based Materials

2018-12-11

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to \$450 Million

2018-12-11

[Read more](#)

#### Health Care/Hospital Recent Releases

#### Medical/Pharmaceuticals Recent Releases